Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 3
2005 5
2006 8
2007 4
2008 4
2009 2
2010 9
2011 3
2012 3
2013 9
2014 9
2015 7
2016 7
2017 9
2018 15
2019 24
2020 14
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

126 results
Results by year
Filters applied: . Clear all
Page 1
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ. Lee M, et al. Among authors: kim yr. Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1. Trials. 2019. PMID: 30651149 Free PMC article.
126 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page